• LifeArc receives $1.2b in Keytruda royalties pharmatimes
    May 28, 2019
    UK-based medical research charity LifeArc has received $1.297 billion from CPPIB Credit Europe for a portion of its royalty interest in MSD’s Keytruda (pembrolizumab).
PharmaSources Customer Service